MX2022009784A - Terapia anti-bcma en trastornos autoinmunes. - Google Patents

Terapia anti-bcma en trastornos autoinmunes.

Info

Publication number
MX2022009784A
MX2022009784A MX2022009784A MX2022009784A MX2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A
Authority
MX
Mexico
Prior art keywords
autoimmune disorders
bcma therapy
bcma
therapy
anca
Prior art date
Application number
MX2022009784A
Other languages
English (en)
Spanish (es)
Inventor
Robert Plenge
Kofi Mensah
Sophie Roy
Dennis Zaller
Jennifer Dovey
Steven Saenz
Jill Henault
Camille Doykan
Jenna Calvino
Xi Jin
Joseph Paquette
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022009784A publication Critical patent/MX2022009784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022009784A 2020-02-12 2021-02-11 Terapia anti-bcma en trastornos autoinmunes. MX2022009784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (1)

Publication Number Publication Date
MX2022009784A true MX2022009784A (es) 2022-09-09

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009784A MX2022009784A (es) 2020-02-12 2021-02-11 Terapia anti-bcma en trastornos autoinmunes.

Country Status (11)

Country Link
US (1) US20240052064A1 (https=)
EP (1) EP4103224A4 (https=)
JP (1) JP7783183B2 (https=)
KR (1) KR20220141306A (https=)
CN (1) CN115551539A (https=)
AU (1) AU2021221123A1 (https=)
BR (1) BR112022014646A2 (https=)
CA (1) CA3169696A1 (https=)
IL (1) IL295471A (https=)
MX (1) MX2022009784A (https=)
WO (1) WO2021163329A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用
WO2026033437A1 (en) * 2024-08-07 2026-02-12 Janssen Biotech, Inc. Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
WO2026037514A1 (en) * 2024-08-13 2026-02-19 Friedrich-Alexander-Universität Erlangen-Nürnberg, in Vertretung des Freistaates Bayern A bispecific binding agent targeting cd3 and bcma for the treatment of autoimmune diseases

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3331910T1 (sl) * 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
CA3287539A1 (en) * 2017-06-21 2026-03-02 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
SG11202003501XA (en) * 2017-11-01 2020-05-28 Juno Therapeutics Inc Antibodies and chimeric antigen receptors specific for b-cell maturation antigen

Also Published As

Publication number Publication date
BR112022014646A2 (pt) 2022-09-13
KR20220141306A (ko) 2022-10-19
JP2023514224A (ja) 2023-04-05
US20240052064A1 (en) 2024-02-15
EP4103224A4 (en) 2023-08-16
CN115551539A (zh) 2022-12-30
JP7783183B2 (ja) 2025-12-09
IL295471A (en) 2022-10-01
WO2021163329A1 (en) 2021-08-19
CA3169696A1 (en) 2021-08-19
AU2021221123A1 (en) 2022-10-06
EP4103224A1 (en) 2022-12-21

Similar Documents

Publication Publication Date Title
MX2022009784A (es) Terapia anti-bcma en trastornos autoinmunes.
SA521422581B1 (ar) أil-7r جسام مضادة للوحدة الثانوية ألفا واستخداماتها
MY209474A (en) Il-2 conjugates and methods of use to treat autoimmune diseases
JOP20200210A1 (ar) أجسام مضادة مساعدة لـ pd-1 واستخداماتها
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
EP4597112A3 (en) Anti-galectin-9 antibodies and uses thereof
WO2018204803A8 (en) Compositions and methods of treating huntington's disease
MY202336A (en) Agonist antibodies that bind human cd137 and uses thereof
AU2016249140A8 (en) Anti-PACAP antibodies and uses thereof
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
WO2021096763A8 (en) Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
SV2011003807A (es) Composiciones y metodos de uso para anticuerpos terapeuticos
PY1794093A (es) Anticuerpo monoclonal o un fragmento de unión a antígeno dirigidos contra cd127
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
MX2018014152A (es) Composiciones y métodos para tratar la enfermedad de huntington.
PH12021553145A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2019009546A (es) Anticuerpos anti-factor d y uso de los mismos.
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
ZA202401321B (en) Anti-cd161 antibodies and uses thereof
WO2020089396A3 (en) Composition and methods of treating inflammatory and autoimmune diseases
WO2022183074A3 (en) Anti-psma antibodies and car-t structures
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
WO2024178202A3 (en) Anti-cd3 antibodies and methods for their use
ZA202006216B (en) Antibodies targeting glycoprotein vi